<DOC>
	<DOCNO>NCT02265874</DOCNO>
	<brief_summary>The purpose study determine nicotine treatment beneficial treatment sarcoidosis . Sarcoidosis disease unknown cause lead inflammation . This disease affect body 's organ .</brief_summary>
	<brief_title>Nicotine Treatment Pulmonary Sarcoidosis : A Clinical Trial Pilot Study</brief_title>
	<detailed_description>Participants randomly divide two group . One group receive nicotine patch use approximately 7 month ; group receive placebo nicotine patch use time period . Both group contact weekly phone first 3 week monthly duration study monitor side effect . The following information sample collect : Questionnaires Medical History Spirometry CT Scans Physical Exam Blood Samples nicotine nicotine metabolite</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Sarcoidosis , Pulmonary</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Adult male female subject ≥ 18 ≤ 75 year age screen eligibility . Eligible adult patient histologically proven sarcoidosis , diagnose least 6 month screen , evidence parenchymal disease chest radiograph , FVC 50 % 85 % predict value , Medical Research Council dyspnea score ( 47 ) least grade 1 . Patients must treat least 10 mg/day prednisone equivalent one immunomodulating agent ( hydroxychloroquine , methotrexate , azathioprine , leflunomide ) &gt; 3 month screen . Doses medication must stable least 1 month study entry . During study , background medication regimen dose remain stable . active tobacco smoking use smokeless tobacco product contain nicotine , active cardiac central nervous system disease , history adverse reaction nicotine nicotinecontaining product , patient extensive irreversible pulmonary fibrosis ( base upon lung biopsy high resolution CT scan criterion ) inability provide consent . The subject exclude smoke history great 20 pack year , diagnosis significant respiratory disorder , sarcoidosis , opinion investigator , would complicate evaluation response treatment ; , history substance abuse ( drug alcohol ) within 3 year prior screen circumstance ( e.g. , psychiatric disease ) could interfere subject 's adherence protocol requirement increase risk drug ( nicotine ) dependence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>